Several complement antibody-therapeutics are currently under development, but only Eculizumab (anti-C5) is approved to treat alternative pathway-associated disorders, aHUS and paroxysmal nocturnal hemoglobinuria (PNH) [35]. This evidence concerns the gene C5 and paroxysmal nocturnal hemoglobinuria.